Pulmonary Arterial Hypertension

Maybe good news for PAH:

Pharmaceutical and biotechnology companies have evinced interest in the PAH markets despite the small patient population. The robust late stage drug pipeline has resulted in in-licensing deals and M&A activity.

Due to a lack of awareness about the disease, the rate of diagnosis and treatment is low, resulting in higher mortality rate among patients diagnosed at a late-stage of the disease.

"The average survival time of patients upon diagnosis is between 3-4 years chiefly due to the low diagnosis rates," says Barath Shankar. "Several patients are unaware of the existence of the disease until progression to a chronic stage.

"Several leading pharmaceutical and biotechnology companies have shown interest in this market. The development of improved therapies, combined with increased awareness is likely to enable the growth of this market